To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-01

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood. One of these infections is caused by a mold called Aspergillus and can be life threatening. Usually doctors give preventive antifungal therapy to try to lower the risk of this infection. Despite this, patients are still at risk of getting fungal infection. This study is thus designed to test Galactomannan - a component of cell wall of Aspergillus and hence detect and treat fungal infection early.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

NCT00462657

Graft Versus Host Disease Infection Leukemia +2 more

UNKNOWN NA

A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients

NCT00163722

Invasive Aspergillosis

COMPLETED PHASE3

Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients

NCT01695512

Invasive Aspergillosis Acute Leukemia Biomarkers +1 more

UNKNOWN

Empirical Versus Preemptive Antifungal Therapy

NCT01288378

Fungal Infection Leukemia Myelodysplastic Syndromes

COMPLETED PHASE3

Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients

NCT01128907

Invasive Aspergillosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The diagnosis of invasive Aspergillosis (IA) remains a challenge in the febrile neutropenic and the hematopoietic stem cell transplant (HSCT) recipients. Recent studies have shown that early diagnosis of IA is possible in this group of high-risk patients. Serial screening of circulating Galactomannan (GM), an epitopic determinant of several antigens secreted by the Aspergillus early in its growth, has been shown to be sensitive and specific in the diagnosis of IA. This test may help us to detect IA early, thereby permitting a pre-emptive strategy to be initiated in high-risk patients. In a prospective, randomized, non-blinded study, we seek to compare the outcome of a novel GM-guided anti-fungal strategy against the conventional empirical antifungal therapy. Patients randomized to the conventional arm will not undergo serial GM monitoring, but will receive standard anti-fungal prophylaxis and standard empirical antifungal therapy in accordance with published guidelines. Patients randomized to the GM arm will receive standard anti-fungal prophylaxis but will not receive empiric anti-fungal therapy unless 2 GM readings are positive. The study aims to determine if such a strategy permits targeted, pre-emptive therapy in those at greatest risk, and spare febrile patients without evidence of fungal infection other than prolonged fever from unnecessary and potentially toxic therapy. It also aims to determine if GM guided pre-emptive antifungal therapy using Amphotericin-B deoxycholate prevents the development of proven or probable invasive aspergillosis (IA). The study will also prospectively evaluate (in a blinded fashion) the use of realtime polymerase chain reaction (RT PCR) assay in the same cohort of patients receiving GM serial monitoring, and investigate its role in the diagnosis and treatment monitoring of invasive Aspergillosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aspergillosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GM test

Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.

Group Type EXPERIMENTAL

Galactomannan antigen monitoring, Aspergillus PCR

Intervention Type BEHAVIORAL

There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.

blood draws

Intervention Type OTHER

Blood is drawn for monitoring of Galactomannan antigen in the blood

blood draws for GM monitoring

Intervention Type OTHER

blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.

Amphotericin-B deoxycholate

Intervention Type DRUG

1-1.5mg/kg, i.v, once a day

blood test

Intervention Type OTHER

Blood will be tested twice a week for the presence of Galactomannan.

Blood test

Intervention Type OTHER

Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)

no GM monitoring

in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Galactomannan antigen monitoring, Aspergillus PCR

There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.

Intervention Type BEHAVIORAL

blood draws

Blood is drawn for monitoring of Galactomannan antigen in the blood

Intervention Type OTHER

blood draws for GM monitoring

blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.

Intervention Type OTHER

Amphotericin-B deoxycholate

1-1.5mg/kg, i.v, once a day

Intervention Type DRUG

blood test

Blood will be tested twice a week for the presence of Galactomannan.

Intervention Type OTHER

Blood test

Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fungizone, Abelcet, AmBisome, Fungisome, Amphocil,

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with newly diagnosed acute leukemia or high risk myelodysplastic syndrome (MDS) receiving induction chemotherapy with expected duration of neutropenia (absolute neutrophil count of \< 500/mL) of at least 10 days
2. Patients with relapsed acute leukemia or MDS receiving salvage chemotherapy with expected duration of neutropenia (absolute neutrophil count of \< 500/mL) of at least 10 days
3. Patients with severe aplastic anemia (SAA) receiving chemotherapy or immunosuppressive therapy using antithymocyte globulin
4. Patients receiving allogeneic/autologous hematopoeitic stem cell transplant (HSCT) using myeloablative conditioning regimens
5. Patients are at least 12 years of age, with Karnofsky score of 70%.?
6. Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC \< 500/ml) of at least 10 days

Exclusion Criteria

1. Patients who are human immunodeficiency virus (HIV) infected
2. Patients with uncontrolled bacteremia or active pulmonary infection at the time of randomisation
3. Patients with pre-existing proven and probable invasive fungal infections, according to the definitions of the invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Disease \[10\].
4. Patients receiving concomitant piperacillin/tazobactam or co-amoxyclavulinic acid
5. Patients on palliative chemotherapy
6. Patients with history of allergy to triazoles
7. Patients with prior history of anaphylactic reaction to conventional amphotericin B
8. Patients with serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin more than 5 times the upper limit of normal or renal impairment with calculated creatinine clearance \< 30ml/min
9. Patients with expected life-expectancy \< 72 hours

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No